Study S001025

Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07468552
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 100
Start: 2026-11-15
Primary completion: 2028-03-15
Lead sponsor: National Institute on Drug Abuse (NIDA)
Conditions: Cannabis Use Disorder
Interventions: DRUG:Tirzepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Maximum Tolerated Dose (MTD) [24 weeks (Treatment Phase)]
Days of Abstinence [24 weeks (Treatment Phase)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.